research chemical comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-01-29. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine in major jurisdictions | Sold as a research chemical; legal status varies |
| Anti-doping status | Prohibited by the World Anti-Doping Agency | Listed under non-approved substances or related category |
| Typical analytical method | LC-MS/MS | Used for detection and confirmation in biological samples |
| Storage temperature | −20 °C or lower for solid | Desiccated and protected from light |
| Common solution solvents | DMSO; ethanol | Aqueous solubility is limited |
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
=== Australian Sports Anti-Doping Authority === Australian Sports Anti-Doping Authority (ASADA) was the governing body behind the restriction and regulation of drug use within Australian sporting events and was established in 2006 by the Australian Government. ASADA designed and delivered education and communication programs, detected and managed anti-doping rule violations, conducted anti-doping investigation cases, monitored the compliance of anti-doping policies, and supported athletes to meet their anti-doping obligations. On July 1, 2020, the functions of the Australian Sports Anti-Doping Authority (ASADA), the National Integrity of Sport (NISU) and the national integrity programs of Sport Australia, were brought together under a new executive agency of the Australian Government called Sport Integrity Australia. Since commencing operations, Sport Integrity Australia (SIA) has been led by CEO David Sharpe . Sport Integrity Australia reports to the Minister for Sport.
=== Differential diagnosis === Seborrhoeic dermatitis can look similar to other skin conditions that share its characteristic dry, flaky, scaly, and inflamed appearance, but have different causes and treatments. Physicians use the history of the individual with the skin condition as well as other tests to identify which disorder is present. Other conditions that may be confused with seborrhoeic dermatitis based on appearance are listed below.
electron transport in the mitochondrial ETC, by shuttling electrons from mitochondrial complexes like nicotinamide adenine dinucleotide (NADH), ubiquinone reductase (complex I), and succinate ubiquinone reductase (complex II), the fatty acids and branched-chain amino acids oxidation (through flavin-linked dehydrogenases) to ubiquinol–cytochrome-c reductase (complex III) of the ETC: CoQ10 participates in fatty acid and glucose metabolism by transferring electrons generated from the reduction of fatty acids and glucose to electron acceptors; antioxidant activity as a lipid-soluble antioxidant together with vitamin E, scavenging reactive oxygen species and protecting cells against oxidative stress, inhibiting the oxidation of proteins, DNA, and use of vitamin E.
Sources: en.wikipedia.org
=== Angiotensin IV === Amino acid sequence: Arg | Val-Tyr-Ile-His-Pro-Phe Angiotensin IV is a hexapeptide that, like angiotensin III, has some lesser activity. Angiotensin IV has a wide range of activities in the central nervous system. The exact identity of AT4 receptors has not been established. There is evidence that the AT4 receptor is insulin-regulated aminopeptidase (IRAP). There is also evidence that angiotensin IV interacts with the HGF system through the c-Met receptor. Synthetic small molecule analogues of angiotensin IV with the ability to penetrate through blood brain barrier have been developed. The AT4 site may be involved in memory acquisition and recall, as well as blood flow regulation. Angiotensin IV and its analogs may also benefit spatial memory tasks such as object recognition and avoidance (conditioned and passive avoidance). Studies have also shown that the usual biological effects of angiotensin IV on the body are not affected by common AT2 receptor antagonists such as the hypertension medication losartan.
{\displaystyle {\begin{aligned}{\frac {\mathbf {D} m}{\mathbf {Dt} }}&={\iiint \limits _{V}}\left({{\frac {\mathbf {D} \rho }{\mathbf {Dt} }}+\rho (\nabla \cdot \mathbf {u} )}\right)dV\\{\frac {\mathbf {D} \rho }{\mathbf {Dt} }}+\rho (\nabla \cdot {\mathbf {u} })&={\frac {\partial \rho }{\partial t}}+({\nabla \rho })\cdot {\mathbf {u} }+{\rho }(\nabla \cdot \mathbf {u} )={\frac {\partial \rho }{\partial t}}+\nabla \cdot ({\rho \mathbf {u} })=0\end{aligned}}}
=== Thin film deposition === Vacuum evaporation is also a form of physical vapor deposition used in the semiconductor, microelectronics, and optical industries. In this context it is used to deposit thin films of material onto surfaces. Such a technique consists of pumping a vacuum chamber to low pressures (<10−5 torr) and heating a material to produce vapor to deposit the material onto a cold surface. The material to be vaporized is typically heated until its vapor pressure is high enough to produce a flux of several Angstroms per second by using an electrically resistive heater or bombardment by a high voltage beam.
4-HO-MET binds to various serotonin receptors and is known to act as an agonist of the serotonin 5-HT2A, 5-HT2B, 5-HT2C, and 5-HT1A receptors. It is thought that the hallucinogenic effects of serotonergic psychedelics like 4-HO-MET are mediated by serotonin 5-HT2A receptor activation.
Sources: en.wikipedia.org
=== Anion exchange resins === Strong base anion (SBA) resins: Type 1 SBA resins: Greatest affinity for the weak acids and commonly present during a water demineralization process. Type 3 SBA resins: Lower chemical stability than Type 1 but better regeneration efficiency. Weak base anion (WBA) resins: Act as acid absorbers; capable of sorbing strong acids with a high capacity and are readily regenerated with caustic.
== The identification of PIDD1 == PIDD, now officially known as PIDD1 (p53-induced death domain protein 1), a transformation of name was necessary to avoid confusion with primary immune deficiency disorders, which are often abbreviated similarly in scientific literature. Notably, no PIDD1 orthologues have been identified in non-vertebrates, and PIDD1 paralogues have not been found in vertebrates. Initially, PIDD1 was also referred to as leucine-rich repeat and death domain containing protein (LRDD) and was independently reported by two research groups in 2000.
== Academia == Ettre was a senior lecturer and adjunct professor at several universities; Veszprém University, Budapest, Hungary (1950–1952), the University of Houston, Texas, United States (1986–1968), Johannes Kepler University, Linz Austria, and the Department of Chemical Engineering at Yale University, New Haven, Connecticut, United States (1977–1978, 1988–200?), where he was adjunct professor and research affiliate. Ettre served as an editor of Chromatographia from 1970 – 1994, when he became a member of the journal's advisory board. He served on the editorial advisory boards of the Journal of Chromatographic Science (1963–1994) and the Journal of Liquid Chromatography (1984–1993), and on the editorial advisory boards of LC/GC Magazine in both the North America and Europe editions, as well as of the Magyar Kemikusok Lapja (Hungarian Chemical Journal). He was the author of the column “Milestones in Chromatography,” in LC/GC Magazine from 1999 until 2008. Ettre was a member of the Commission on Analytical Nomenclature of the International Union of Pure and Applied Chemistry (I.U.P.A.C.) from 1982 to 1990, where he was responsible for the development of the "Unified Nomenclature for Chromatography" issued in 1993.
Sources: en.wikipedia.org
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.
Laboratories typically use LC-MS/MS to detect SR9009 and related compounds in urine or blood. The method is sensitive but depends on sample collection timing. Confirmatory analysis follows quality-control procedures.
Solid material is generally kept cold, dry, and protected from light. Solutions are often stored in sealed containers at low temperature. Stability beyond recommended periods is not well documented.
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.